RGS4 inhibits angiotensin II signaling and macrophage localization during renal reperfusion injury independent of vasospasm

Kidney International

Volumn 87, Issue 4, 2015, Pages 771-783

  Pang, Paul ^a   Jin, Xiaohua ^b   Proctor, Brandon M ^b   Farley, Michelle ^c   Roy, Nilay ^d   Chin, Matthew S ^e   Von Andrian, Ulrich H ^f,g   Vollmann, Elisabeth ^f   Perro, Mario ^f   Hoffman, Ryan J ^h   Chung, Joseph ^a   Chauhan, Nikita ^a   Mistri, Murti ^a   Muslin, Anthony J ^b   Bonventre, Joseph V ^a   Siedlecki, Andrew M ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d PARTNERS HEALTHCARE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g HARVARD UNIVERSITY   (United States)

^h WESLEYAN UNIVERSITY   (United States)

Author keywords

Acute kidney injury; Ischemia reperfusion; Renin angiotensin system

Indexed keywords

ANGIOTENSIN II; CREATININE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; RANTES; RGS4 PROTEIN; UREA; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; RGS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BLOOD VESSEL DIAMETER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY PERFUSION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENAL REPERFUSION INJURY; REPERFUSION INJURY; SMOOTH MUSCLE FIBER; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE; VASOSPASM; WILD TYPE; ANIMAL; AORTA; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; KIDNEY CIRCULATION; KIDNEY CORTEX; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; VASCULARIZATION; VASOCONSTRICTION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; AORTA; ARTERIOLES; CELLS, CULTURED; CHEMOKINE CCL5; HUMANS; KIDNEY CORTEX; MACROPHAGES; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RECEPTOR, ANGIOTENSIN, TYPE 2; RENAL CIRCULATION; REPERFUSION INJURY; RGS PROTEINS; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 84926520868     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.364     Document Type: Article

References (43)

1. Gurley SB, Griffiths RC, Mendelsohn ME et al. Renal actions of RGS2 control blood pressure. J Am Soc Nephrol 2010; 21: 1847-1851.
2. Siedlecki AM, Jin X, Thomas W et al. RGS4, a GTPase activator, improves renal function in ischemia-reperfusion injury. Kidney Int 2011; 80: 263-271.
3. Takata Y, Liu J, Yin F et al. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA 2008; 105: 4277-4282.
4. Barish GD, Atkins AR, Downes M et al. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 2008; 105: 4271-4276.
5. Harris IS, Treskov I, Rowley MW et al. G-protein signaling participates in the development of diabetic cardiomyopathy. Diabetes 2004; 53: 3082-3090.
6. Heximer SP, Blumer KJ. RGS proteins: Swiss army knives in seventransmembrane domain receptor signaling networks. Sci STKE 2007; 2007pe2.
7. Cifelli C, Rose RA, Zhang H et al. RGS4 regulates parasympathetic signaling and heart rate control in the sinoatrial node. CirRes 2008; 103: 527-535.
8. Zarzuelo MJ, Jimenez R, Galindo P et al. Antihypertensive effects of peroxisome proliferator-activated receptor-beta activation in spontaneously hypertensive rats. Hypertension 2011; 58: 733-743.
9. Kleemann P, Papa D, Vigil-Cruz S et al. Functional reconstitution of the human chemokine receptor CXCR4 with G(i)/G (o)-proteins in Sf9 insect cells. Naunyn-Schmiedeberg's ArchPharmacol 2008; 378: 261-274.
10. Tamirisa P, Blumer KJ, Muslin AJ. RGS4 inhibits G-protein signaling in cardiomyocytes. Circulation 1999; 99: 441-447.
11. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78: 539-552.
12. Chen J, Chen JK, Nagai K et al. EGFR signaling promotes TGFbetadependent renal fibrosis. J Am SocNephrol 2012; 23: 215-224.
13. Adams GN, LaRusch GA, Stavrou E et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 2011; 117: 3929-3937.
14. Alvarez A, Cerda-Nicolas M, Naim Abu Nabah Y et al. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 2004; 104: 402-408.
15. Zhou Z, Hu CP, Wang CJ et al. Calcitonin gene-related peptide inhibits angiotensin II-induced endothelial progenitor cells senescence through up-regulation of klotho expression. Atherosclerosis 2010; 213: 92-101.
16. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121: 4210-4221.
17. Wilhelm SM, Simonson MS, Robinson AV et al. Endothelin up-regulation and localization following renal ischemia and reperfusion. Kidney Int 1999; 55: 1011-1018.
18. Arendshorst WJ, Brannstrom K, Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 1999; 10(Suppl 11): S149-S161.
19. Gulmen S, Kiris I, Narin C et al. Tezosentan reduces the renal injury induced by abdominal aortic ischemia-reperfusion in rats. J Surg Res 2009; 157: e7-e13.
20. Danilov SM, Sadovnikova E, Scharenborg N et al. Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol 2003; 31: 1301-1309.
21. Komine N, Khang S, Wead LM et al. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002; 39: 159-164.
22. Ding J, Guzman JN, Tkatch T et al. RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neurosci 2006; 9: 832-842.
23. Winden KD, Oldham MC, Mirnics K et al. The organization of the transcriptional network in specific neuronal classes. Mol Syst Biol 2009; 5: 291.
24. Siedlecki A, Anderson JR, Jin X et al. RGS4 controls renal blood flow and inhibits cyclosporine-mediated nephrotoxicity. Am J Transplant 2010; 10: 231-241.
25. Lee JJ, Bretthorst GL, Derdeyn CP et al. Dynamic susceptibility contrast MRI with localized arterial input functions. Magn Reson Med 2010; 63: 1305-1314.
26. Jordan NJ, Watson ML, Williams RJ et al. Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br J Pharmacol 1997; 122: 749-757.
27. Dubey RK, Roy A, Overbeck HW. Culture of renal arteriolar smooth muscle cells. Mitogenic responses to angiotensin II. Circ Res 1992; 71: 1143-1152.
28. Wirth A, Benyo Z, Lukasova M et al. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat Med 2008; 14: 64-68.
29. Basile DP, Leonard EC, Beal AG et al. Persistent oxidative stress following renal ischemia-reperfusion injury increases ANG II hemodynamic and fibrotic activity. Am J Physiol Renal Physiol 2012; 302: F1494-F1502.
30. Rovner AS, Murphy RA, Owens GK. Expression of smooth muscle and nonmuscle myosin heavy chains in cultured vascular smooth muscle cells. J Biol Chem 1986; 261: 14740-14745.
31. Fu W, Wojtkiewicz G, Weissleder R et al. Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat Immunol 2012; 13: 361-368.
32. Piqueras L, Kubes P, Alvarez A et al. Angiotensin II induces leukocyteendothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation 2000; 102: 2118-2123.
33. Esteban V, Lorenzo O, Ruperez M et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 2004; 15: 1514-1529.
34. Wolf G, Wenzel U, Burns KD et al. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 2002; 61: 1986-1995.
35. Wolf G, Ziyadeh FN, Thaiss F et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997; 100: 1047-1058.
36. Ullevig S, Zhao Q, Lee CF et al. NADPH oxidase 4 mediates monocyte priming and accelerated chemotaxis induced by metabolic stress. Arterioscler Thromb Vasc Biol 2012; 32: 415-426.
37. Guzik TJ, Hoch NE, Brown KA et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204: 2449-2460.
38. Snoeijs MG, Hoogland PR, Boonen B et al. Thromboxane receptor signalling in renal ischemia reperfusion injury. Free Radic Res 2011; 45: 699-706.
39. Song KS, Choi YH, Kim JM et al. Suppression of prostaglandin E2-induced MUC5AC overproduction by RGS4 in the airway. American J Physiol Lung Cell Mol Physiol 2009; 296: L684-L692.
40. Eppig JT, Blake JA, Bult CJ et al. The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res 2012; 40(Database issue): D881-D886.
41. Kakoki M, McGarrah RW, Kim HS et al. Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2007; 104: 7576-7581.
42. Wang Q, Traynor JR. Opioid-induced down-regulation of RGS4: role of ubiquitination and implications for receptor cross-talk. J Biol Chem 2011; 286: 7854-7864.
43. Young S, Struys E, Wood T. Quantification of creatine and guanidinoacetate using GC-MS and LC-MS/MS for the detection of cerebral creatine deficiency syndromes. Cur Protoc Hum Genet 2007; Chapter 17: Unit 17 13.